TMX
group
Home
>
Quotes & Charts
> News
Resverlogix Corp. (RVX)
Exchange: Toronto Stock Exchange
$
3.630
May 24, 2013, 1:06 AM EDT
Change:
0.02 (0.55%)
Volume:
156,074
Day Low
3.560
Day High
3.680
52 Week Low
1.290
52 Week High
3.830
Real-time Streaming Quotes
Add to Portfolio
Create Alert
Free Annual Reports
52 Week Information
close
52 Week High
2013-05-21
High: 3.830
52 Week Low
2012-06-05
Low: 1.290
Quote
Charting
News
Company
Financials
Price History
Options
Research
News Headlines for Resverlogix Corp.
Wednesday, May 1, 2013
7:00 AM EDT
Resverlogix's Board Approves Arrangement to Spin-Out RVX Therapeutics Inc. and Confirms Special Meeting of Shareholders
- Canada Newswire
7:00 AM EDT
Resverlogix's Board Approves Arrangement to Spin-Out RVX Therapeutics Inc. and Confirms Special Meeting of Shareholders
- PR Newswire
Thursday, April 18, 2013
7:00 AM EDT
Resverlogix Completes Dosing In ASSURE Clinical Trial
- PR Newswire
7:00 AM EDT
Resverlogix Completes Dosing in ASSURE Clinical Trial
- PR Newswire
7:00 AM EDT
Resverlogix Completes Dosing In ASSURE Clinical Trial
- Canada Newswire
Monday, April 8, 2013
7:00 AM EDT
Resverlogix to Spin-out RVX Therapeutics Inc. to Shareholders
- PR Newswire
7:00 AM EDT
Resverlogix to Spin-out RVX Therapeutics Inc. to Shareholders
- Canada Newswire
7:00 AM EDT
Resverlogix to Spin-out RVX Therapeutics Inc. to Shareholders
- PR Newswire
7:00 AM EDT
Resverlogix to Spin-out RVX Therapeutics Inc. to Shareholders
- PR Newswire
Monday, March 11, 2013
8:00 AM EDT
Resverlogix Secures Increase to Citibank Loan to $38.8 million
- PR Newswire
8:00 AM EDT
Resverlogix Secures Increase to Citibank Loan to $38.8 million
- Canada Newswire
Thursday, January 31, 2013
2:13 PM EST
Resverlogix comments on steady climb of share price
- Canada Newswire
Tuesday, October 16, 2012
7:30 AM EDT
Resverlogix Initiates Phase 2 Clinical Trial of RVX-208 in Patients with Pre-Diabetes Mellitus
- Canada Newswire
Wednesday, September 26, 2012
7:30 AM EDT
Resverlogix Completes Enrollment In ASSURE Trial
- Canada Newswire
Tuesday, August 28, 2012
8:00 AM EDT
Resverlogix's BET Protein Inhibitor RVX-208 Meets Primary Endpoint in SUSTAIN Clinical Trial in Patients With High Risk Cardiovascular Disease
- Canada Newswire
Copyright ©
QuoteMedia
. Data delayed 15 minutes unless otherwise indicated. View
delay times
for all exchanges.
Market Data powered by
QuoteMedia
. See the
QuoteMedia
and
TMX Group
Terms of Use.